Enlivex Ltd.

Enlivex Ltd. is a clinical-stage macrophage reprogramming immunotherapy company based in Ness Ziona, Israel, founded in 2005. The company's core mission is to develop innovative cell therapies, primarily Allocetra, designed to reprogram macrophages into their homeostatic state to address various inflammatory diseases and rebalance immune hyper-responses. Beyond its therapeutic pipeline, Enlivex has adopted a unique dual strategy, positioning itself as a "quality longevity company powered by a Prediction Markets Treasury," integrating digital asset management into its financial model.

Enlivex's primary product candidate, Allocetra, is an off-the-shelf cell therapy currently in clinical development for several indications. These include organ dysfunction and failure caused by sepsis (Phase II), and various forms of osteoarthritis, such as moderate knee osteoarthritis (Phase I/II, Phase IIb), end-stage knee osteoarthritis (Phase I/II), Basal thumb osteoarthritis (Phase I/II), and Psoriatic arthritis (Phase I/II). The company aims to restore mobility, independence, and functional life, particularly in aging populations, by targeting unmet medical needs in inflammatory and autoimmune diseases.

In a significant corporate development, the company formally changed its name from Enlivex Therapeutics Ltd. to Enlivex Ltd. in February 2026. Recent notable activities include the appointment of former Italian Prime Minister Matteo Renzi to its board of directors in November 2025. Enlivex reported a net income of $1.23 billion for the full year 2025, largely driven by the appreciation of its treasury and treasury-related derivative assets, specifically RAIN tokens, which are part of its prediction markets treasury strategy. The company also received FDA clearance and a second regulatory approval for a Phase IIb clinical trial of Allocetra in age-related primary moderate-to-severe knee osteoarthritis, with top-line data anticipated in 2027. As of April 2026, its RAIN token holdings exceeded 78 billion tokens, valued at $567 million, and the token was listed on the HTX cryptocurrency exchange. Oren Hershkovitz serves as the CEO, with Shai Novik as the Executive Chairman.

Latest updates

Enlivex Lists RAIN Token on HTX, Bolstering Digital Treasury Liquidity

Event summary

  • Enlivex listed its RAIN token on HTX, a cryptocurrency exchange with over 59 million users and $3.3 trillion in annual trading volume.
  • The listing aims to increase accessibility, global reach, and liquidity for Enlivex’s primary digital treasury asset.
  • Enlivex currently holds approximately 78.8 billion RAIN tokens, valued at $567 million as of April 27, 2026.
  • RAIN serves as the governance and utility token for a decentralized prediction markets protocol built on the Arbitrum network.

The big picture

Enlivex’s strategy of combining longevity therapeutics with a digital asset treasury is a relatively novel approach, and the HTX listing represents a key step in validating this model. The company’s significant RAIN token holdings ($567 million) highlight the importance of this digital asset strategy to its overall financial health. The listing on a top-10 exchange like HTX signals an attempt to legitimize RAIN and attract broader participation in the prediction markets ecosystem.

What we're watching

Liquidity Impact
The listing’s effect on RAIN token liquidity will be crucial to monitor, as increased trading volume could impact Enlivex’s treasury value and potentially its share price.
Regulatory Scrutiny
Increased exchange listings and digital asset treasury strategies may draw greater regulatory scrutiny, potentially impacting Enlivex’s operations and future plans.
Protocol Adoption
The success of the RAIN token is intrinsically linked to the adoption and utility of the underlying prediction markets protocol, and its growth will dictate the long-term value of Enlivex’s treasury.

Enlivex Boosts RAIN Holdings, Signals Continued Prediction Markets Bet

Event summary

  • Enlivex now holds 78,819,756,062 RAIN tokens, valued at approximately $567 million as of April 27, 2026.
  • The acquisition was made through exercising an option to purchase RAIN tokens from the Rain Foundation at $0.0033 per token, a 55% discount to the market price.
  • Enlivex’s option to acquire up to 272,121,212,121 RAIN tokens from the Rain Foundation expires on December 31, 2027.
  • The company’s treasury strategy focuses on acquiring RAIN tokens, the token of the Rain protocol, a decentralized prediction markets infrastructure.

The big picture

Enlivex’s strategy of combining longevity therapeutics development with a prediction markets treasury is a unique approach, reflecting a belief in the potential of decentralized prediction markets as an asset class. The significant RAIN holdings, representing a $567 million position, underscore the company’s commitment to this strategy, but also expose it to the inherent volatility of the cryptocurrency market. This move signals a broader trend of companies exploring alternative treasury strategies beyond traditional assets.

What we're watching

Option Utilization
The pace at which Enlivex exercises its remaining option to purchase RAIN tokens will reveal the company’s conviction in the protocol’s long-term value and its willingness to deploy capital at the agreed-upon price.
Market Volatility
How RAIN’s price volatility impacts Enlivex’s treasury value will be a key indicator of the risks associated with this strategy and its potential to create or erode shareholder value.
Institutional Adoption
Whether the ‘growing institutional appetite’ for prediction markets, as cited by Enlivex, translates into sustained demand for RAIN and supports the company’s treasury strategy remains to be seen.

Enlivex Allocetra Data to be Presented at OARSI Congress

Event summary

  • Enlivex will present Phase IIa data for Allocetra at the OARSI 2026 World Congress in West Palm Beach, Florida, from April 23-26, 2026.
  • The data includes 3-month and 6-month endpoints demonstrating statistically significant improvement in pain and function compared to placebo in patients with moderate-to-severe knee osteoarthritis (KOA).
  • The trial focused on patients ≥60 years old, representing over 50% of the KOA market.
  • Enlivex will also present pharmacological characterization data supporting Allocetra’s immunomodulating mechanism of action.

The big picture

Enlivex’s strategy of combining longevity therapeutics with a prediction markets treasury (RAIN token) represents a novel approach to value creation. The Allocetra Phase IIa data is a key milestone for the company, as it targets a large and underserved market of patients with age-related osteoarthritis. Success hinges on demonstrating a clear clinical advantage and navigating the regulatory pathway for a novel cell therapy.

What we're watching

Clinical Validation
The durability of the 6-month efficacy data will be critical; a lack of sustained benefit could significantly impact Allocetra’s commercial prospects.
Mechanism of Action
Further elucidation of Allocetra’s pharmacological characterization and immunomodulating mechanism will be necessary to differentiate it from existing osteoarthritis treatments and support regulatory approval.
Market Adoption
The acceptance of Allocetra by rheumatologists and patient adoption rates will depend on the perceived benefit relative to existing, often less expensive, treatment options.
CID: 1247